Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination With Immune Checkpoint Inhibition in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

NCT07182149 is registered in ClinicalTrials.gov with Normunity AccelCo, Inc. as lead sponsor.

NCT NCT07182149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07182149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination With Immune Checkpoint Inhibition in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Lead sponsor
Normunity AccelCo, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
October 30, 2025
Completion date
October 31, 2028
Enrollment
150 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, endometrial cancer, escc, esophageal adenocarcinoma, gastric adenocarcinoma, gej adenocarcinoma, hnscc, nsclc, ovarian cancer, triple negative breast cancer (tnbc)